Filip Roudnicky

List of Publications by Year
in descending order

21 papers	1,176 citations	623734 14 h-index	677142 22 g-index
23 all docs	23 docs citations	23 times ranked	2591 citing authors

#	Article	IF	Citations
1	An integrated expression atlas of miRNAs and their promoters in human and mouse. Nature Biotechnology, 2017, 35, 872-878.	17.5	456
2	Endocan Is Upregulated on Tumor Vessels in Invasive Bladder Cancer Where It Mediates VEGF-A–Induced Angiogenesis. Cancer Research, 2013, 73, 1097-1106.	0.9	150
3	Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer. Scientific Reports, 2015, 5, 9188.	3.3	119
4	Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway. ACS Chemical Biology, 2019, 14, 2215-2223.	3.4	74
5	Functional Genomics for Cancer Drug Target Discovery. Cancer Cell, 2020, 38, 31-43.	16.8	46
6	Identification of a combination of transcription factors that synergistically increases endothelial cell barrier resistance. Scientific Reports, 2020, 10, 3886.	3.3	40
7	Inducers of the endothelial cell barrier identified through chemogenomic screening in genome-edited hPSC-endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 19854-19865.	7.1	35
8	CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer. Disease Markers, 2015, 2015, 1-8.	1.3	34
9	Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer. Journal of Clinical Pathology, 2015, 68, 819-824.	2.0	34
10	Inflammation-Induced Lymph Node Lymphangiogenesis Is Reversible. American Journal of Pathology, 2012, 180, 874-879.	3.8	32
11	High expression of insulin receptor on tumour-associated blood vessels in invasive bladder cancer predicts poor overall and progression-free survival. Journal of Pathology, 2017, 242, 193-205.	4.5	24
12	Steering Target Selectivity and Potency by Fragment-Based De Novo Drug Design. Angewandte Chemie - International Edition, 2013, 52, 10006-10009.	13.8	23
13	De novo design and optimization of Aurora A kinase inhibitors. Chemical Science, 2013, 4, 1229.	7.4	23
14	Alternative transcription of a shorter, non-anti-angiogenic thrombospondin-2 variant in cancer-associated blood vessels. Oncogene, 2018, 37, 2573-2585.	5.9	22
15	Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis. Cell Stem Cell, 2020, 27, 147-157.e7.	11.1	17
16	Monolayer Generation of Vascular Endothelial Cells from Human Pluripotent Stem Cells. Methods in Molecular Biology, 2019, 1994, 17-29.	0.9	8
17	Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling. American Journal of Pathology, 2020, 190, 1960-1970.	3.8	8
18	Requirements for Using iPSC-Based Cell Models for Assay Development in Drug Discovery. Advances in Biochemical Engineering/Biotechnology, 2017, 163, 207-220.	1.1	7

#	Article	IF	Citations
19	Transcriptional profiling of macrophage and tumor cell interactions in vitro. Genomics Data, 2016, 8, 1-3.	1.3	5
20	Modeling the Effects of Severe Metabolic Disease by Genome Editing of hPSC-Derived Endothelial Cells Reveals an Inflammatory Phenotype. International Journal of Molecular Sciences, 2019, 20, 6201.	4.1	3
21	Preventing VEGF-Mediated Vascular Permeability by Experimentally Potentiating BBB Characteristics in Endothelial Cells. Methods in Molecular Biology, 2022, 2475, 259-274.	0.9	0